C. Blake Gilks
A5032474916- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Cancer Genomics and Diagnostics
- Cervical Cancer and HPV Research
- Sarcoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Uterine Myomas and Treatments
- Prostate Cancer Treatment and Research
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Colorectal and Anal Carcinomas
- Reproductive Biology and Fertility
- HER2/EGFR in Cancer Research
- Endometriosis Research and Treatment
- Cancer-related Molecular Pathways
- Chromatin Remodeling and Cancer
- Molecular Biology Techniques and Applications
- Congenital Diaphragmatic Hernia Studies
- Neuroendocrine Tumor Research Advances
- AI in cancer detection
- RNA modifications and cancer
- Genomics, phytochemicals, and oxidative stress
- Virus-based gene therapy research
- Endoplasmic Reticulum Stress and Disease
- Genital Health and Disease
Vancouver General Hospital
2016-2025
University of British Columbia
2016-2025
Vancouver Coastal Health
2025
Vancouver Coastal Health Research Institute
2005-2025
University of British Columbia Hospital
1994-2024
Anna Needs Neuroblastoma Answers
2024
Health Sciences Centre
2015-2024
Molecular Oncology (United States)
2019-2024
Spinal Cord Injury BC
2024
Turku University Hospital
2024
Ovarian clear-cell and endometrioid carcinomas may arise from endometriosis, but the molecular events involved in this transformation have not been described.We sequenced whole transcriptomes of 18 ovarian 1 carcinoma cell line found somatic mutations ARID1A (the AT-rich interactive domain 1A [SWI-like] gene) 6 samples. encodes BAF250a, a key component SWI–SNF chromatin remodeling complex. We an additional 210 second measured BAF250a expression by means immunohistochemical analysis 455...
Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most biomarker studies current treatment protocols for women this disease not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have identified in these subtypes. We examined variation expression rates between subtypes, how influences correlations stage at diagnosis or...
Classification of endometrial carcinomas (ECs) by morphologic features is inconsistent, and yields limited prognostic predictive information. A new system for classification based on the molecular categories identified in The Cancer Genome Atlas proposed. Genomic data from (TCGA) support into four prognostically significant subgroups; we used TCGA set to develop surrogate assays that could replicate classification, but without need labor-intensive cost-prohibitive genomic methodology....
BACKGROUND Classification of endometrial carcinomas (ECs) by morphologic features is irreproducible and imperfectly reflects tumor biology. The authors developed the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), a molecular classification system based on Genome Atlas genomic subgroups, sought to confirm both feasibility prognostic ability in new, large cohort ECs. METHODS Immunohistochemistry (IHC) presence or absence mismatch repair (MMR) proteins (to identify MMR...
Germline truncating mutations in DICER1, an endoribonuclease the RNase III family that is essential for processing microRNAs, have been observed families with pleuropulmonary blastoma-family tumor and dysplasia syndrome. Mutation carriers are at risk nonepithelial ovarian tumors, notably sex cord-stromal tumors.We sequenced whole transcriptomes or exomes of 14 tumors noted closely clustered region DICER1 encoding IIIb domain four samples. We then this additional certain other queried effect...
High-grade serous ovarian cancer (HGSC) is characterized by poor outcome, often attributed to the emergence of treatment-resistant subclones. We sought measure degree genomic diversity within primary, untreated HGSCs examine natural state tumour evolution prior therapy. performed exome sequencing, copy number analysis, targeted amplicon deep sequencing and gene expression profiling on 31 spatially temporally separated HGSC specimens (six patients), including masses, distant metastases...
Patients with high-grade subtypes of endometrial carcinoma (grade 3 endometrioid, serous, clear cell, or carcinosarcoma) have a relatively poor prognosis. The specific subtype may be used to guide patient management, but there is little information on the reproducibility diagnosis in cases carcinoma. Fifty-six diagnosed as were identified from pathology archives Vancouver General Hospital. All slides for each case reviewed independently by pathologists, who tumor subtype(s) and assigned...
Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns TILs by histotype and relation to other clinical factors.
Purpose Human epidermal growth factor receptor 2 gene (HER2) is associated with a poorer outcome in node-positive breast cancer, but the results are conflicting node-negative disease. This study assessed prognostic impact of HER2 overexpression/amplification large series cancers. Patients and Methods A tissue microarray (TMA) was constructed consisting 4,444 invasive cancers diagnosed British Columbia from 1986 to 1992. Within this series, 2,026 patients were node negative, whom 70% did not...
Abstract Pathogenic somatic missense mutations within the DNA polymerase epsilon ( POLE ) exonuclease domain define important subtype of ultramutated tumours (‘ ‐ultramutated’) novel molecular classification endometrial carcinoma (EC). However, clinical implementation this classifier requires systematic evaluation pathogenicity mutations. To address this, we examined base changes, tumour mutational burden (TMB), microsatellite instability (MSI) status, variant frequency, and results from six...
Abstract The classification of endometrial carcinomas is based on pathological assessment tumour cell type; the different types (endometrioid, serous, carcinosarcoma, mixed, undifferentiated, and clear cell) are associated with distinct molecular alterations. This current system for high‐grade subtypes, in particular distinction between endometrioid (EEC‐3) serous (ESC), limited its reproducibility prognostic abilities. Therefore, a search specific classifiers to improve carcinoma...
Endometrial stromal sarcoma (ESS) is a genetically heterogenous group of uterine sarcomas, which almost half are associated with JAZF1 rearrangement. We recently identified novel genetic fusion between YWHAE and FAM22A/B in ESS harboring t(10;17)(q22;p13) herein describe the clinicopathologic features 13 YWHAE-FAM22 cases (11 primary 3 metastatic) compare them 20 Ten 11 tumors contained morphologically high-grade areas composed round cells arranged nests delicate capillary network. The tumor...
14-3-3 proteins are ubiquitously expressed regulators of various cellular functions, including proliferation, metabolism, and differentiation, altered expression is associated with development progression cancer. We report a transforming oncoprotein, which we identified through conventional cytogenetics whole-transcriptome sequencing analysis as highly recurrent genetic mechanism in clinically aggressive form uterine sarcoma: high-grade endometrial stromal sarcoma (ESS). The oncoprotein...
Ovarian clear cell adenocarcinoma (OCCA) is an uncommon histotype that generally refractory to platinum-based chemotherapy. We analyze here the most comprehensive gene expression and copy number data sets, date, identify potential therapeutic targets of OCCA.Gene DNA were carried out using primary human OCCA tumor samples, findings confirmed by immunohistochemistry on tissue microarrays. Circulating interleukin (IL) 6 levels measured in serum from patients with or high-grade serous cancers...
TP53 mutations are considered a surrogate biomarker of the serous-like 'copy number high' molecular subtype endometrial carcinoma (EC). In ovarian carcinoma, p53 immunohistochemistry (IHC) accurately reflects mutational status with almost 100% specificity but its performance in EC has not been established. This study tested whether IHC reliably predicts identified by next-generation sequencing (NGS) biopsy samples for all ECs and as part classification algorithm after exclusion cases...